Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin

Canada - English - Health Canada

sanis health inc - clarithromycin - granules for suspension - 250mg - clarithromycin 250mg - other macrolides

Canada - English - Health Canada

sivem pharmaceuticals ulc - clarithromycin - tablet - 250mg - clarithromycin 250mg - other macrolides

Canada - English - Health Canada

sivem pharmaceuticals ulc - clarithromycin - tablet - 500mg - clarithromycin 500mg - other macrolides

Canada - English - Health Canada

sanis health inc - clarithromycin - tablet - 250mg - clarithromycin 250mg - other macrolides

Canada - English - Health Canada

sanis health inc - clarithromycin - tablet - 500mg - clarithromycin 500mg - other macrolides

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who cannot use first line therapy. clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to staphylococ

United States - English - NLM (National Library of Medicine)

life line home care services, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) acute maxillary sinusitis due to haemophilus influenzae, moraxella catarrhalis , or streptococcus pneumoniae acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae community-acquired pneumonia due to haemophilus influenzae, mycoplasma

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clarithromycin, quantity: 250 mg - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch; magnesium stearate; povidone; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 8000; triacetin; quinoline yellow aluminium lake; polydextrose - clarithromycin (clarithro) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below.,1. acute streptococcal pharyngitis.,2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae (see section 4.4 special warnings and precautions for use regarding sensitivity testing);,3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes (see section 4.4 special warnings and precautions for use regarding sensitivity testing);,4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other anti-mycobacterial agents.,5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts < 75 cells/mm3 (see section 4.4 special warnings and precautions for use). disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis.,6. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae.,7. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection.,clarithromycin (clarithro) is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below.,1. acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes.,2. community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophilia.,3. skin and skin structure infections (e.g. impetigo).,4. disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immuno-compromised children, including those with hiv infection or aids.,5. acute otitis media.,note.,1. penicillins are the drug of first choice in the treatment of acute otitis media.,2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.,3. there is insufficient evidence of efficacy to support the use of clarithromycin in acute bronchitis in young children.,4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.,consideration should be given to official guidance on the appropriate use of antibacterial agents.

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin